Long-term Study of Ciclosporin for Atopic Dermatitis

Severe Atopic Dermatitis Clinical Trial

Official title:
Long-term Study of Ciclosporin for Atopic Dermatitis

Status Completed

Clinical Trial Summary

In patients with severe adult atopic dermatitis, the safety and efficacy of OL27-400MEPC will be assessed by repeating oral administration at a dose of 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8-12 weeks and recovery until 52 weeks after starting treatment

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00232063
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	May 2004

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT03052348` - Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Active Comparator in Atopic Dermatitis.	N/A
	Completed	`NCT00232076` - Verification Study of Ciclosporin for Atopic Dermatitis	Phase 3